Skip to main content
. 2010 Aug 11;2(4):e00040. doi: 10.1042/AN20100015

Figure 6. Hsp70 is required for the in vivo efficacy of KU-32 against indices of diabetic sensory neuropathy.

Figure 6

Hsp70 KO mice were rendered diabetic for 12 weeks and then treated with weekly doses of vehicle or 20 mg/kg KU-32 for 6 weeks. (a) After 18 weeks of diabetes, MNCV and SNCV decreased in vehicle-treated mice and weekly treatment with KU-32 for 6 weeks did not reverse these deficits. *P<0.01 versus untreated control; ∧P<0.01 versus vehicle+KU-32. Two weeks after the induction of diabetes, mechanical sensitivity (b) and thermal sensitivity (b) were assessed weekly. Although 12 weeks of diabetes produced a significant mechanical and thermal hypoalgesia, weekly treatment with KU-32 had no effect on improving the sensory thresholds.*P<0.01 compared with the time-matched untreated control. ∧P<0.01 compared with time-matched vehicle+KU-32.